Madrigal Pharmaceuticals (MDGL) Competitors $311.62 -1.49 (-0.48%) (As of 05:27 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MDGL vs. BIIB, UTHR, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, HALO, and IONSShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Halozyme Therapeutics Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability. Does the media favor BIIB or MDGL? In the previous week, Biogen had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for Biogen and 0 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.14 beat Biogen's score of 0.65 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Biogen Positive Madrigal Pharmaceuticals Positive Do institutionals and insiders hold more shares of BIIB or MDGL? 87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, BIIB or MDGL? Biogen has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.42, suggesting that its stock price is 142% less volatile than the S&P 500. Do analysts rate BIIB or MDGL? Biogen presently has a consensus price target of $242.68, suggesting a potential upside of 63.14%. Madrigal Pharmaceuticals has a consensus price target of $347.33, suggesting a potential upside of 12.41%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 16 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.45Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 Does the MarketBeat Community prefer BIIB or MDGL? Biogen received 1351 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.77% of users gave Biogen an outperform vote while only 67.70% of users gave Madrigal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes180871.77% Underperform Votes71128.23% Madrigal PharmaceuticalsOutperform Votes45767.70% Underperform Votes21832.30% Is BIIB or MDGL more profitable? Biogen has a net margin of 16.81% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.81% 14.98% 8.59% Madrigal Pharmaceuticals N/A -71.78%-53.25% Which has preferable valuation & earnings, BIIB or MDGL? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.84B2.20$1.16B$11.0713.44Madrigal Pharmaceuticals$76.81M87.74-$373.63M-$25.08-12.32 SummaryBiogen beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Ad DTIWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!Click here to get the details. Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.74B$6.66B$5.21B$9.13BDividend YieldN/A2.96%4.96%4.20%P/E Ratio-12.3210.6086.9917.20Price / Sales87.74199.631,140.13123.78Price / CashN/A57.1543.2737.84Price / Book15.055.184.875.00Net Income-$373.63M$150.98M$120.16M$225.21M7 Day Performance-0.60%2.39%2.07%3.81%1 Month Performance-5.85%-5.17%17.15%2.69%1 Year Performance33.55%7.68%29.44%18.12% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals4.1414 of 5 stars$311.62-0.5%$347.33+11.5%+35.3%$6.80B$76.81M-12.4390Positive NewsBIIBBiogen4.8648 of 5 stars$149.22+1.9%$242.68+62.6%-41.5%$21.74B$9.61B13.487,570Analyst DowngradeShort Interest ↓UTHRUnited Therapeutics4.4465 of 5 stars$361.99+0.7%$370.86+2.4%+63.7%$16.16B$2.76B15.901,168Positive NewsNBIXNeurocrine Biosciences4.9462 of 5 stars$136.04+0.5%$166.29+22.2%+5.8%$13.77B$2.24B36.471,400INCYIncyte4.6286 of 5 stars$69.92+1.6%$76.29+9.1%+10.3%$13.47B$4.08B499.462,524BMRNBioMarin Pharmaceutical4.9986 of 5 stars$66.17+0.8%$94.20+42.4%-30.6%$12.61B$2.75B39.623,401Short Interest ↓Positive NewsEXASExact Sciences4.8132 of 5 stars$59.17-0.4%$72.94+23.3%-22.2%$10.95B$2.69B-50.576,600Short Interest ↓Positive NewsEXELExelixis4.6999 of 5 stars$33.24-0.2%$32.44-2.4%+40.9%$9.49B$2.08B21.311,310Short Interest ↓RGENRepligen4.2481 of 5 stars$144.87+0.3%$185.20+27.8%-19.1%$8.12B$639.92M-391.531,783Positive NewsHALOHalozyme Therapeutics4.9639 of 5 stars$47.16+0.4%$61.11+29.6%+30.2%$6.00B$947.36M15.62390Analyst ForecastNews CoverageIONSIonis Pharmaceuticals4.1213 of 5 stars$35.78+0.4%$60.65+69.5%-29.0%$5.65B$803.07M-14.66800 Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Halozyme Therapeutics Competitors Ionis Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MDGL) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
